Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells.
Frecot DI, Blaess S, Wagner TR, Kaiser PD, Traenkle B, Fandrich M, Jakobi M, Scholz AM, Nueske S, Schneiderhan-Marra N, Gouttefangeas C, Kneilling M, Pichler BJ, Sonanini D, Rothbauer U. Frecot DI, et al. Among authors: gouttefangeas c. Front Immunol. 2024 Oct 15;15:1480091. doi: 10.3389/fimmu.2024.1480091. eCollection 2024. Front Immunol. 2024. PMID: 39474429 Free PMC article.
Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells.
Wagner TR, Blaess S, Leske IB, Frecot DI, Gramlich M, Traenkle B, Kaiser PD, Seyfried D, Maier S, Rezza A, Sônego F, Thiam K, Pezzana S, Zeck A, Gouttefangeas C, Scholz AM, Nueske S, Maurer A, Kneilling M, Pichler BJ, Sonanini D, Rothbauer U. Wagner TR, et al. Among authors: gouttefangeas c. Front Immunol. 2023 Dec 18;14:1264179. doi: 10.3389/fimmu.2023.1264179. eCollection 2023. Front Immunol. 2023. PMID: 38164132 Free PMC article.
CAF-immune cell crosstalk and its impact in immunotherapy.
Maia A, Schöllhorn A, Schuhmacher J, Gouttefangeas C. Maia A, et al. Among authors: gouttefangeas c. Semin Immunopathol. 2023 Mar;45(2):203-214. doi: 10.1007/s00281-022-00977-x. Epub 2022 Dec 8. Semin Immunopathol. 2023. PMID: 36480035 Free PMC article. Review.
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2.
Özbay Kurt FG, Lepper A, Gerhards C, Roemer M, Lasser S, Arkhypov I, Bitsch R, Bugert P, Altevogt P, Gouttefangeas C, Neumaier M, Utikal J, Umansky V. Özbay Kurt FG, et al. Among authors: gouttefangeas c. Front Immunol. 2022 Oct 12;13:1012526. doi: 10.3389/fimmu.2022.1012526. eCollection 2022. Front Immunol. 2022. PMID: 36311732 Free PMC article.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Löffler MW, et al. Among authors: gouttefangeas c. Clin Cancer Res. 2022 Jun 13;28(12):2555-2566. doi: 10.1158/1078-0432.CCR-21-4424. Clin Cancer Res. 2022. PMID: 35421231 Clinical Trial.
Integrin activation enables rapid detection of functional Vδ1+ and Vδ2+ γδ T cells.
Herold N, Schöllhorn A, Feile A, Gaißler A, Mohrholz A, Pawelec G, Löffler MW, Dimitrov S, Gouttefangeas C, Wistuba-Hamprecht K. Herold N, et al. Among authors: gouttefangeas c. Eur J Immunol. 2022 May;52(5):730-736. doi: 10.1002/eji.202149682. Epub 2022 Feb 21. Eur J Immunol. 2022. PMID: 35133647 Free article.
114 results